Treatment options for older adults with Acute Myeloid Leukaemia (AML) are limited. Abnormalities in DNA structure play an important role in the development of AML. New drugs, called epigenetic therapies, reverse these abnormalities, are clinically active and relatively well tolerated. The most widely used epigenetic therapy in AML is azacitidine, which produces responses in 15% of patients. Trials have demonstrated higher response rates when azacitdine is combined with drugs such as vorinostat. This is the first randomised trial to study whether the addition of vorinostat to azacitidine improves the response rate and overall survival of patients with AML.
Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible
| Chief Investigator: Professor Charles Craddock |
|
| Sponsor: University of Birmingham |
|
| Funders: Bloodwise (Trials Acceleration Programme) and Celgene |
|
| Disease Site: Acute Myeloid Leukaemia and Myelodysplastic Syndrome |
|
| Trial Type: Clinical Trial of an Investigational Medicinal Product |
|
| Status: Follow-up |
|
| UKCRN Study ID: 12452 |
|
| Open to new sites? No |
|
| Recruitment start date: 12-Nov-2012 |
|
| Recruitment end date: 30-Sep-2015 |
|
| CRCTU Trial Management Team: Haematology Team |
|
| Trial E-mail Address: ravva@trials.bham.ac.uk |
|